Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
Description: Dermira, Inc., a specialty biopharmaceutical company, focuses on the development and commercialization of medical dermatology products to dermatologists and their patients primarily in the United States. The company?s late-stage product candidates comprise Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor, which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04, a anticholinergic product that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01, a sebum inhibitor, which has completed a Phase IIa clinical trial for the treatment of acne. Its early-stage programs in preclinical development include DRM02, an inhibitor of phosphodiesterase-4 for the treatment of inflammatory skin diseases; and DRM05, a photodynamic therapy for the treatment of acne. Dermira, Inc. has a collaboration agreement with UCB Pharma S.A. for the development and commercialization of Cimzia. The company was formerly known
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||Sales Growth - Q/Q||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-17.27%||ROE||-20.31%||ROI|
|Current Ratio||10.38||Quick Ratio||Long Term Debt/Equity||0.02||Debt Ratio||0.09|
|Gross Margin||Operating Margin||Net Profit Margin||Dividend Payout Ratio|
|Cash From Financing Activities||40 K||Cash From Investing Activities||1.86 M||Cash From Operating Activities||-5.12 M||Gross Profit|
|Net Profit||-14.04 M||Operating Profit||-14.23 M||Total Assets||165.61 M||Total Current Assets||124.49 M|
|Total Current Liabilities||12 M||Total Debt||1.94 M||Total Liabilities||24.75 M||Total Revenue|
|High 52 week||30.93||Low 52 week||6.19||Last close||7.28||Last change||1.39%|
|RSI||61.43||Average true range||0.44||Beta||1.02||Volume||98.87 K|
|Simple moving average 20 days||6.68%||Simple moving average 50 days||-13.53%||Simple moving average 200 days||-26.29%|
|Performance Week||9.64%||Performance Month||2.25%||Performance Quart||-43.7%||Performance Half||-29.66%|
|Performance Year||-73.81%||Performance Year-to-date||1.25%||Volatility daily||3.14%||Volatility weekly||7.02%|
|Volatility monthly||14.38%||Volatility yearly||49.82%||Relative Volume||231.19%||Average Volume||689.88 K|
|New High||New Low|
2019-03-20 10:28:02 | Dermira DERM Catches Eye: Stock Jumps 12%
2019-03-19 19:36:06 | Dermira Prices $130.0 Million Public Offering of Common Stock
2019-03-19 16:00:00 | Why Dermira Stock Jumped Again Today
2019-03-19 10:52:02 | Company News For Mar 19, 2019
2019-03-19 08:31:14 | See what the IHS Markit Score report has to say about Dermira Inc.
2019-03-19 06:06:00 | Can Dermira Stock Keep Soaring?
2019-03-18 16:30:24 | Dermira Announces Proposed Public Offering of Common Stock
2019-03-18 14:22:58 | Why Dermira Stock Is Soaring More than 80% Today
2019-03-18 12:31:42 | Dermira News: Why DERM Stock Is Skyrocketing Today
2019-03-18 12:14:00 | Why Dermira's Shares Are Doubling Today
2019-03-18 11:15:37 | Dermira Investors Get 100% One-Day Payoff a Year After Acne Flop
2019-03-18 10:00:00 | Dermira Shares Rocket After Successful Phase II Eczema Treatment Study
2019-03-18 09:53:04 | Why Dermira Shares Are Shooting Higher After Last Year's Disappointment
2019-03-18 07:24:00 | Dermira shares soar 83% premarket on news of positive trial of dermatitis treatment
2019-03-12 10:28:35 | See what the IHS Markit Score report has to say about Dermira Inc.
2019-03-06 08:05:03 | See what the IHS Markit Score report has to say about Dermira Inc.
2019-03-05 16:00:00 | Dermira to Present at the Cowen and Company 39th Annual Health Care Conference
2019-03-05 08:03:56 | See what the IHS Markit Score report has to say about Dermira Inc.
2019-03-01 08:51:01 | Implied Volatility Surging for Dermira DERM Stock Options
2019-02-27 03:05:49 | Edited Transcript of DERM earnings conference call or presentation 26-Feb-19 9:30pm GMT
2019-02-26 14:30:00 | Dermira Inc to Host Earnings Call
2019-02-21 16:01:00 | Dermira to Present at the 8th Annual SVB Leerink Global Healthcare Conference
2019-02-08 08:07:14 | See what the IHS Markit Score report has to say about Dermira Inc.
2019-02-07 08:02:15 | See what the IHS Markit Score report has to say about Dermira Inc.
2019-02-06 08:07:45 | See what the IHS Markit Score report has to say about Dermira Inc.
2019-02-04 08:02:10 | See what the IHS Markit Score report has to say about Dermira Inc.
2019-01-29 08:03:13 | See what the IHS Markit Score report has to say about Dermira Inc.
2019-01-17 08:03:49 | See what the IHS Markit Score report has to say about Dermira Inc.
2019-01-15 08:03:35 | See what the IHS Markit Score report has to say about Dermira Inc.
2019-01-09 08:03:56 | See what the IHS Markit Score report has to say about Dermira Inc.
2019-01-08 12:50:13 | At biotech's big event, a chance for execs to shape LGBTQ diversity on boards
2018-12-20 08:04:11 | See what the IHS Markit Score report has to say about Dermira Inc.
2018-12-18 22:28:01 | Do Hedge Funds Love Dermira Inc DERM?
2018-12-17 08:04:24 | See what the IHS Markit Score report has to say about Dermira Inc.
2018-12-11 17:07:35 | Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635c4
2018-12-05 14:58:37 | Is Dermira Inc’s NASDAQ:DERM CEO Paid At A Competitive Rate?
2018-12-04 07:30:00 | Dermira Enters into Credit Facility with Athyrium Capital Management
2018-11-28 08:40:00 | Report: Exploring Fundamental Drivers Behind CASI Pharmaceuticals, Booking, Enstar Group, Madrigal Pharmaceuticals, Dermira, and Kaiser Aluminum — New Horizons, Emerging Trends, and Upcoming Developments
2018-11-24 08:03:33 | See what the IHS Markit Score report has to say about Dermira Inc.
2018-11-19 08:00:00 | Dermira to Present at Evercore ISI HealthCONx Conference